Valuation: Gabather AB

Market Cap 12.09M 1.22M 1.09M 1.01M 914K 1.71M 116M 1.73M 4.8M 60.57M 4.57M 4.47M 192M P/E 2024
-1.07x
P/E 2025 -1.13x
Enterprise Value 8.94M 900K 808K 746K 677K 1.26M 85.51M 1.28M 3.55M 44.82M 3.38M 3.31M 142M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
91.04%
Yield 2024 *
-
Yield 2025 -
1 day-2.94%
1 week-12.39%
Current month-29.29%
1 month-27.21%
3 months-35.71%
6 months-49.23%
Current year-27.74%
1 week 0.02
Extreme 0.0182
0.02
1 month 0.02
Extreme 0.0182
0.03
Current year 0.02
Extreme 0.0182
0.1
1 year 0.02
Extreme 0.0182
0.1
3 years 0.02
Extreme 0.0182
4.2
5 years 0.02
Extreme 0.0182
6.45
10 years 0.02
Extreme 0.0182
53.2
Manager TitleAgeSince
Chief Executive Officer - 01/10/2018
Chief Operating Officer - 01/01/2018
Chief Tech/Sci/R&D Officer - 01/01/2018
Director TitleAgeSince
Director/Board Member - 01/09/2014
Director/Board Member 60 03/11/2014
Chairman - 01/01/2021
Change 5-day change 1-year change 3-year change Capi.($)
-2.94%-12.39%-35.71%-99.10% 1.25M
-3.10%-4.19%+32.67%+59.47% 65.28B
+0.33%+0.33%+10.16%+78.07% 54.57B
+0.16%+1.73%+9.89%+102.10% 53.59B
-0.75%+1.38%+24.89%+50.91% 45.03B
-1.30%-4.80%+16.05%+114.76% 42.17B
+1.26%-5.26%+221.12%+900.64% 39.42B
-0.74%-4.46%+11.00%+44.65% 32.71B
+1.11%+15.18%+60.27%+49.33% 26.5B
+3.18%-6.72%+25.35%-8.75% 24.01B
Average -0.28%-0.50%+37.57%+129.21% 38.33B
Weighted average by Cap. -0.35%-0.80%+42.52%+153.42%

Financials

2024 2025
Net sales - -
Net income -7.75M -780K -700K -647K -586K -1.1M -74.12M -1.11M -3.08M -38.85M -2.93M -2.87M -123M -4.65M -468K -420K -388K -352K -658K -44.47M -666K -1.85M -23.31M -1.76M -1.72M -73.92M
Net Debt -878K -88.37K -79.31K -73.23K -66.41K -124K -8.39M -126K -349K -4.4M -332K -325K -13.95M -3.14M -316K -284K -262K -238K -444K -30.05M -450K -1.25M -15.75M -1.19M -1.16M -49.94M
Projected Income Statement - Annual - Gabather AB
Logo Gabather AB
Gabather AB is a Sweden-based company engaged pharmaceutical industry. The Company develops drug candidates for the treatment of several diseases originating in the central nervous system (CNS). The Company mainly focuses on anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as conginition-enhancing treatments, including Alzheimer’s disease.
Employees
2
Date Price Change Volume
27/10/26 SEK 0.0198 -2.94% 467,271
26/10/26 SEK 0.0204 -2.86% 3,020,977
23/10/26 SEK 0.0210 -7.08% 3,931,027
22/10/26 SEK 0.0226 +2.73% 3,778,040
21/10/26 SEK 0.0220 -2.65% 3,153,995
  1. Stock Market
  2. Stocks
  3. GABA Stock